Global AAV-based Gene Therapy Products Market Growth 2026-2032
The global AAV-based Gene Therapy Products market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
AAV-based gene therapy products utilize adeno-associated virus (AAV) vectors as delivery vehicles to transfer therapeutic genes into target cells for the treatment of various genetic disorders and diseases. AAV vectors are non-pathogenic viruses that can efficiently infect a wide range of cells and have a low immunogenicity profile, making them suitable candidates for gene therapy applications. In AAV-based gene therapy, the therapeutic gene of interest is inserted into the AAV vector's genome, and the vector is then administered to the patient, typically via intravenous injection or direct injection into the affected tissue. Once inside the target cells, the AAV vector delivers the therapeutic gene, allowing it to be expressed and produce the desired therapeutic protein. AAV-based gene therapy products hold significant promise for the treatment of inherited genetic disorders, as well as acquired diseases such as certain types of cancer and neurodegenerative disorders, offering potential long-term therapeutic benefits with a single administration.
United States market for AAV-based Gene Therapy Products is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for AAV-based Gene Therapy Products is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for AAV-based Gene Therapy Products is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key AAV-based Gene Therapy Products players cover uniQure, Spark Therapeutics, AveXis (Novartis), PTC Therapeutics, BioMarin, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?AAV-based Gene Therapy Products Industry Forecast? looks at past sales and reviews total world AAV-based Gene Therapy Products sales in 2025, providing a comprehensive analysis by region and market sector of projected AAV-based Gene Therapy Products sales for 2026 through 2032. With AAV-based Gene Therapy Products sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world AAV-based Gene Therapy Products industry.
This Insight Report provides a comprehensive analysis of the global AAV-based Gene Therapy Products landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on AAV-based Gene Therapy Products portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global AAV-based Gene Therapy Products market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for AAV-based Gene Therapy Products and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global AAV-based Gene Therapy Products.
This report presents a comprehensive overview, market shares, and growth opportunities of AAV-based Gene Therapy Products market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global AAV-based Gene Therapy Products market?
What factors are driving AAV-based Gene Therapy Products market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do AAV-based Gene Therapy Products market opportunities vary by end market size?
How does AAV-based Gene Therapy Products break out by Type, by Application?
AAV-based gene therapy products utilize adeno-associated virus (AAV) vectors as delivery vehicles to transfer therapeutic genes into target cells for the treatment of various genetic disorders and diseases. AAV vectors are non-pathogenic viruses that can efficiently infect a wide range of cells and have a low immunogenicity profile, making them suitable candidates for gene therapy applications. In AAV-based gene therapy, the therapeutic gene of interest is inserted into the AAV vector's genome, and the vector is then administered to the patient, typically via intravenous injection or direct injection into the affected tissue. Once inside the target cells, the AAV vector delivers the therapeutic gene, allowing it to be expressed and produce the desired therapeutic protein. AAV-based gene therapy products hold significant promise for the treatment of inherited genetic disorders, as well as acquired diseases such as certain types of cancer and neurodegenerative disorders, offering potential long-term therapeutic benefits with a single administration.
United States market for AAV-based Gene Therapy Products is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for AAV-based Gene Therapy Products is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for AAV-based Gene Therapy Products is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key AAV-based Gene Therapy Products players cover uniQure, Spark Therapeutics, AveXis (Novartis), PTC Therapeutics, BioMarin, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?AAV-based Gene Therapy Products Industry Forecast? looks at past sales and reviews total world AAV-based Gene Therapy Products sales in 2025, providing a comprehensive analysis by region and market sector of projected AAV-based Gene Therapy Products sales for 2026 through 2032. With AAV-based Gene Therapy Products sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world AAV-based Gene Therapy Products industry.
This Insight Report provides a comprehensive analysis of the global AAV-based Gene Therapy Products landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on AAV-based Gene Therapy Products portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global AAV-based Gene Therapy Products market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for AAV-based Gene Therapy Products and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global AAV-based Gene Therapy Products.
This report presents a comprehensive overview, market shares, and growth opportunities of AAV-based Gene Therapy Products market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- AAV2
- AAV8
- AAV9
- Others
- Haematology
- Ophthalmology
- Neurology
- Musculoskeletal
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- uniQure
- Spark Therapeutics
- AveXis (Novartis)
- PTC Therapeutics
- BioMarin
- Sarepta Therapeutics
- Roche
- Pfizer
- CSL Behring
- Sangamo Therapeutics
- Biogen
- Freeline Therapeutics
- Coave Therapeutics
- MeiraGTx
- RegenxBio
- Asklepios Biopharmaceutical
- Audentes Therapeutics
- Neurophth
- Belief BioMed
What is the 10-year outlook for the global AAV-based Gene Therapy Products market?
What factors are driving AAV-based Gene Therapy Products market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do AAV-based Gene Therapy Products market opportunities vary by end market size?
How does AAV-based Gene Therapy Products break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global AAV-based Gene Therapy Products Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for AAV-based Gene Therapy Products by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for AAV-based Gene Therapy Products by Country/Region, 2021, 2025 & 2032
2.2 AAV-based Gene Therapy Products Segment by Type
2.2.1 AAV2
2.2.2 AAV8
2.2.3 AAV9
2.2.4 Others
2.2.5 AAV-based Gene Therapy Products Sales by Type
2.2.5.1 Global AAV-based Gene Therapy Products Sales Market Share by Type (2021-2026)
2.2.5.2 Global AAV-based Gene Therapy Products Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global AAV-based Gene Therapy Products Sale Price by Type (2021-2026)
2.3 AAV-based Gene Therapy Products Segment by Application
2.3.1 Haematology
2.3.2 Ophthalmology
2.3.3 Neurology
2.3.4 Musculoskeletal
2.3.5 Others
2.3.6 AAV-based Gene Therapy Products Sales by Application
2.3.6.1 Global AAV-based Gene Therapy Products Sale Market Share by Application (2021-2026)
2.3.6.2 Global AAV-based Gene Therapy Products Revenue and Market Share by Application (2021-2026)
2.3.6.3 Global AAV-based Gene Therapy Products Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global AAV-based Gene Therapy Products Breakdown Data by Company
3.1.1 Global AAV-based Gene Therapy Products Annual Sales by Company (2021-2026)
3.1.2 Global AAV-based Gene Therapy Products Sales Market Share by Company (2021-2026)
3.2 Global AAV-based Gene Therapy Products Annual Revenue by Company (2021-2026)
3.2.1 Global AAV-based Gene Therapy Products Revenue by Company (2021-2026)
3.2.2 Global AAV-based Gene Therapy Products Revenue Market Share by Company (2021-2026)
3.3 Global AAV-based Gene Therapy Products Sale Price by Company
3.4 Key Manufacturers AAV-based Gene Therapy Products Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers AAV-based Gene Therapy Products Product Location Distribution
3.4.2 Players AAV-based Gene Therapy Products Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR AAV-BASED GENE THERAPY PRODUCTS BY GEOGRAPHIC REGION
4.1 World Historic AAV-based Gene Therapy Products Market Size by Geographic Region (2021-2026)
4.1.1 Global AAV-based Gene Therapy Products Annual Sales by Geographic Region (2021-2026)
4.1.2 Global AAV-based Gene Therapy Products Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic AAV-based Gene Therapy Products Market Size by Country/Region (2021-2026)
4.2.1 Global AAV-based Gene Therapy Products Annual Sales by Country/Region (2021-2026)
4.2.2 Global AAV-based Gene Therapy Products Annual Revenue by Country/Region (2021-2026)
4.3 Americas AAV-based Gene Therapy Products Sales Growth
4.4 APAC AAV-based Gene Therapy Products Sales Growth
4.5 Europe AAV-based Gene Therapy Products Sales Growth
4.6 Middle East & Africa AAV-based Gene Therapy Products Sales Growth
5 AMERICAS
5.1 Americas AAV-based Gene Therapy Products Sales by Country
5.1.1 Americas AAV-based Gene Therapy Products Sales by Country (2021-2026)
5.1.2 Americas AAV-based Gene Therapy Products Revenue by Country (2021-2026)
5.2 Americas AAV-based Gene Therapy Products Sales by Type (2021-2026)
5.3 Americas AAV-based Gene Therapy Products Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC AAV-based Gene Therapy Products Sales by Region
6.1.1 APAC AAV-based Gene Therapy Products Sales by Region (2021-2026)
6.1.2 APAC AAV-based Gene Therapy Products Revenue by Region (2021-2026)
6.2 APAC AAV-based Gene Therapy Products Sales by Type (2021-2026)
6.3 APAC AAV-based Gene Therapy Products Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe AAV-based Gene Therapy Products by Country
7.1.1 Europe AAV-based Gene Therapy Products Sales by Country (2021-2026)
7.1.2 Europe AAV-based Gene Therapy Products Revenue by Country (2021-2026)
7.2 Europe AAV-based Gene Therapy Products Sales by Type (2021-2026)
7.3 Europe AAV-based Gene Therapy Products Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa AAV-based Gene Therapy Products by Country
8.1.1 Middle East & Africa AAV-based Gene Therapy Products Sales by Country (2021-2026)
8.1.2 Middle East & Africa AAV-based Gene Therapy Products Revenue by Country (2021-2026)
8.2 Middle East & Africa AAV-based Gene Therapy Products Sales by Type (2021-2026)
8.3 Middle East & Africa AAV-based Gene Therapy Products Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of AAV-based Gene Therapy Products
10.3 Manufacturing Process Analysis of AAV-based Gene Therapy Products
10.4 Industry Chain Structure of AAV-based Gene Therapy Products
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 AAV-based Gene Therapy Products Distributors
11.3 AAV-based Gene Therapy Products Customer
12 WORLD FORECAST REVIEW FOR AAV-BASED GENE THERAPY PRODUCTS BY GEOGRAPHIC REGION
12.1 Global AAV-based Gene Therapy Products Market Size Forecast by Region
12.1.1 Global AAV-based Gene Therapy Products Forecast by Region (2027-2032)
12.1.2 Global AAV-based Gene Therapy Products Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global AAV-based Gene Therapy Products Forecast by Type (2027-2032)
12.7 Global AAV-based Gene Therapy Products Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 uniQure
13.1.1 uniQure Company Information
13.1.2 uniQure AAV-based Gene Therapy Products Product Portfolios and Specifications
13.1.3 uniQure AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 uniQure Main Business Overview
13.1.5 uniQure Latest Developments
13.2 Spark Therapeutics
13.2.1 Spark Therapeutics Company Information
13.2.2 Spark Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
13.2.3 Spark Therapeutics AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Spark Therapeutics Main Business Overview
13.2.5 Spark Therapeutics Latest Developments
13.3 AveXis (Novartis)
13.3.1 AveXis (Novartis) Company Information
13.3.2 AveXis (Novartis) AAV-based Gene Therapy Products Product Portfolios and Specifications
13.3.3 AveXis (Novartis) AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 AveXis (Novartis) Main Business Overview
13.3.5 AveXis (Novartis) Latest Developments
13.4 PTC Therapeutics
13.4.1 PTC Therapeutics Company Information
13.4.2 PTC Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
13.4.3 PTC Therapeutics AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 PTC Therapeutics Main Business Overview
13.4.5 PTC Therapeutics Latest Developments
13.5 BioMarin
13.5.1 BioMarin Company Information
13.5.2 BioMarin AAV-based Gene Therapy Products Product Portfolios and Specifications
13.5.3 BioMarin AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 BioMarin Main Business Overview
13.5.5 BioMarin Latest Developments
13.6 Sarepta Therapeutics
13.6.1 Sarepta Therapeutics Company Information
13.6.2 Sarepta Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
13.6.3 Sarepta Therapeutics AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Sarepta Therapeutics Main Business Overview
13.6.5 Sarepta Therapeutics Latest Developments
13.7 Roche
13.7.1 Roche Company Information
13.7.2 Roche AAV-based Gene Therapy Products Product Portfolios and Specifications
13.7.3 Roche AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Roche Main Business Overview
13.7.5 Roche Latest Developments
13.8 Pfizer
13.8.1 Pfizer Company Information
13.8.2 Pfizer AAV-based Gene Therapy Products Product Portfolios and Specifications
13.8.3 Pfizer AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Pfizer Main Business Overview
13.8.5 Pfizer Latest Developments
13.9 CSL Behring
13.9.1 CSL Behring Company Information
13.9.2 CSL Behring AAV-based Gene Therapy Products Product Portfolios and Specifications
13.9.3 CSL Behring AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 CSL Behring Main Business Overview
13.9.5 CSL Behring Latest Developments
13.10 Sangamo Therapeutics
13.10.1 Sangamo Therapeutics Company Information
13.10.2 Sangamo Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
13.10.3 Sangamo Therapeutics AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Sangamo Therapeutics Main Business Overview
13.10.5 Sangamo Therapeutics Latest Developments
13.11 Biogen
13.11.1 Biogen Company Information
13.11.2 Biogen AAV-based Gene Therapy Products Product Portfolios and Specifications
13.11.3 Biogen AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Biogen Main Business Overview
13.11.5 Biogen Latest Developments
13.12 Freeline Therapeutics
13.12.1 Freeline Therapeutics Company Information
13.12.2 Freeline Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
13.12.3 Freeline Therapeutics AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Freeline Therapeutics Main Business Overview
13.12.5 Freeline Therapeutics Latest Developments
13.13 Coave Therapeutics
13.13.1 Coave Therapeutics Company Information
13.13.2 Coave Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
13.13.3 Coave Therapeutics AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Coave Therapeutics Main Business Overview
13.13.5 Coave Therapeutics Latest Developments
13.14 MeiraGTx
13.14.1 MeiraGTx Company Information
13.14.2 MeiraGTx AAV-based Gene Therapy Products Product Portfolios and Specifications
13.14.3 MeiraGTx AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 MeiraGTx Main Business Overview
13.14.5 MeiraGTx Latest Developments
13.15 RegenxBio
13.15.1 RegenxBio Company Information
13.15.2 RegenxBio AAV-based Gene Therapy Products Product Portfolios and Specifications
13.15.3 RegenxBio AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 RegenxBio Main Business Overview
13.15.5 RegenxBio Latest Developments
13.16 Asklepios Biopharmaceutical
13.16.1 Asklepios Biopharmaceutical Company Information
13.16.2 Asklepios Biopharmaceutical AAV-based Gene Therapy Products Product Portfolios and Specifications
13.16.3 Asklepios Biopharmaceutical AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Asklepios Biopharmaceutical Main Business Overview
13.16.5 Asklepios Biopharmaceutical Latest Developments
13.17 Audentes Therapeutics
13.17.1 Audentes Therapeutics Company Information
13.17.2 Audentes Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
13.17.3 Audentes Therapeutics AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Audentes Therapeutics Main Business Overview
13.17.5 Audentes Therapeutics Latest Developments
13.18 Neurophth
13.18.1 Neurophth Company Information
13.18.2 Neurophth AAV-based Gene Therapy Products Product Portfolios and Specifications
13.18.3 Neurophth AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Neurophth Main Business Overview
13.18.5 Neurophth Latest Developments
13.19 Belief BioMed
13.19.1 Belief BioMed Company Information
13.19.2 Belief BioMed AAV-based Gene Therapy Products Product Portfolios and Specifications
13.19.3 Belief BioMed AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Belief BioMed Main Business Overview
13.19.5 Belief BioMed Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global AAV-based Gene Therapy Products Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for AAV-based Gene Therapy Products by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for AAV-based Gene Therapy Products by Country/Region, 2021, 2025 & 2032
2.2 AAV-based Gene Therapy Products Segment by Type
2.2.1 AAV2
2.2.2 AAV8
2.2.3 AAV9
2.2.4 Others
2.2.5 AAV-based Gene Therapy Products Sales by Type
2.2.5.1 Global AAV-based Gene Therapy Products Sales Market Share by Type (2021-2026)
2.2.5.2 Global AAV-based Gene Therapy Products Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global AAV-based Gene Therapy Products Sale Price by Type (2021-2026)
2.3 AAV-based Gene Therapy Products Segment by Application
2.3.1 Haematology
2.3.2 Ophthalmology
2.3.3 Neurology
2.3.4 Musculoskeletal
2.3.5 Others
2.3.6 AAV-based Gene Therapy Products Sales by Application
2.3.6.1 Global AAV-based Gene Therapy Products Sale Market Share by Application (2021-2026)
2.3.6.2 Global AAV-based Gene Therapy Products Revenue and Market Share by Application (2021-2026)
2.3.6.3 Global AAV-based Gene Therapy Products Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global AAV-based Gene Therapy Products Breakdown Data by Company
3.1.1 Global AAV-based Gene Therapy Products Annual Sales by Company (2021-2026)
3.1.2 Global AAV-based Gene Therapy Products Sales Market Share by Company (2021-2026)
3.2 Global AAV-based Gene Therapy Products Annual Revenue by Company (2021-2026)
3.2.1 Global AAV-based Gene Therapy Products Revenue by Company (2021-2026)
3.2.2 Global AAV-based Gene Therapy Products Revenue Market Share by Company (2021-2026)
3.3 Global AAV-based Gene Therapy Products Sale Price by Company
3.4 Key Manufacturers AAV-based Gene Therapy Products Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers AAV-based Gene Therapy Products Product Location Distribution
3.4.2 Players AAV-based Gene Therapy Products Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR AAV-BASED GENE THERAPY PRODUCTS BY GEOGRAPHIC REGION
4.1 World Historic AAV-based Gene Therapy Products Market Size by Geographic Region (2021-2026)
4.1.1 Global AAV-based Gene Therapy Products Annual Sales by Geographic Region (2021-2026)
4.1.2 Global AAV-based Gene Therapy Products Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic AAV-based Gene Therapy Products Market Size by Country/Region (2021-2026)
4.2.1 Global AAV-based Gene Therapy Products Annual Sales by Country/Region (2021-2026)
4.2.2 Global AAV-based Gene Therapy Products Annual Revenue by Country/Region (2021-2026)
4.3 Americas AAV-based Gene Therapy Products Sales Growth
4.4 APAC AAV-based Gene Therapy Products Sales Growth
4.5 Europe AAV-based Gene Therapy Products Sales Growth
4.6 Middle East & Africa AAV-based Gene Therapy Products Sales Growth
5 AMERICAS
5.1 Americas AAV-based Gene Therapy Products Sales by Country
5.1.1 Americas AAV-based Gene Therapy Products Sales by Country (2021-2026)
5.1.2 Americas AAV-based Gene Therapy Products Revenue by Country (2021-2026)
5.2 Americas AAV-based Gene Therapy Products Sales by Type (2021-2026)
5.3 Americas AAV-based Gene Therapy Products Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC AAV-based Gene Therapy Products Sales by Region
6.1.1 APAC AAV-based Gene Therapy Products Sales by Region (2021-2026)
6.1.2 APAC AAV-based Gene Therapy Products Revenue by Region (2021-2026)
6.2 APAC AAV-based Gene Therapy Products Sales by Type (2021-2026)
6.3 APAC AAV-based Gene Therapy Products Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe AAV-based Gene Therapy Products by Country
7.1.1 Europe AAV-based Gene Therapy Products Sales by Country (2021-2026)
7.1.2 Europe AAV-based Gene Therapy Products Revenue by Country (2021-2026)
7.2 Europe AAV-based Gene Therapy Products Sales by Type (2021-2026)
7.3 Europe AAV-based Gene Therapy Products Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa AAV-based Gene Therapy Products by Country
8.1.1 Middle East & Africa AAV-based Gene Therapy Products Sales by Country (2021-2026)
8.1.2 Middle East & Africa AAV-based Gene Therapy Products Revenue by Country (2021-2026)
8.2 Middle East & Africa AAV-based Gene Therapy Products Sales by Type (2021-2026)
8.3 Middle East & Africa AAV-based Gene Therapy Products Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of AAV-based Gene Therapy Products
10.3 Manufacturing Process Analysis of AAV-based Gene Therapy Products
10.4 Industry Chain Structure of AAV-based Gene Therapy Products
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 AAV-based Gene Therapy Products Distributors
11.3 AAV-based Gene Therapy Products Customer
12 WORLD FORECAST REVIEW FOR AAV-BASED GENE THERAPY PRODUCTS BY GEOGRAPHIC REGION
12.1 Global AAV-based Gene Therapy Products Market Size Forecast by Region
12.1.1 Global AAV-based Gene Therapy Products Forecast by Region (2027-2032)
12.1.2 Global AAV-based Gene Therapy Products Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global AAV-based Gene Therapy Products Forecast by Type (2027-2032)
12.7 Global AAV-based Gene Therapy Products Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 uniQure
13.1.1 uniQure Company Information
13.1.2 uniQure AAV-based Gene Therapy Products Product Portfolios and Specifications
13.1.3 uniQure AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 uniQure Main Business Overview
13.1.5 uniQure Latest Developments
13.2 Spark Therapeutics
13.2.1 Spark Therapeutics Company Information
13.2.2 Spark Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
13.2.3 Spark Therapeutics AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Spark Therapeutics Main Business Overview
13.2.5 Spark Therapeutics Latest Developments
13.3 AveXis (Novartis)
13.3.1 AveXis (Novartis) Company Information
13.3.2 AveXis (Novartis) AAV-based Gene Therapy Products Product Portfolios and Specifications
13.3.3 AveXis (Novartis) AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 AveXis (Novartis) Main Business Overview
13.3.5 AveXis (Novartis) Latest Developments
13.4 PTC Therapeutics
13.4.1 PTC Therapeutics Company Information
13.4.2 PTC Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
13.4.3 PTC Therapeutics AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 PTC Therapeutics Main Business Overview
13.4.5 PTC Therapeutics Latest Developments
13.5 BioMarin
13.5.1 BioMarin Company Information
13.5.2 BioMarin AAV-based Gene Therapy Products Product Portfolios and Specifications
13.5.3 BioMarin AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 BioMarin Main Business Overview
13.5.5 BioMarin Latest Developments
13.6 Sarepta Therapeutics
13.6.1 Sarepta Therapeutics Company Information
13.6.2 Sarepta Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
13.6.3 Sarepta Therapeutics AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Sarepta Therapeutics Main Business Overview
13.6.5 Sarepta Therapeutics Latest Developments
13.7 Roche
13.7.1 Roche Company Information
13.7.2 Roche AAV-based Gene Therapy Products Product Portfolios and Specifications
13.7.3 Roche AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Roche Main Business Overview
13.7.5 Roche Latest Developments
13.8 Pfizer
13.8.1 Pfizer Company Information
13.8.2 Pfizer AAV-based Gene Therapy Products Product Portfolios and Specifications
13.8.3 Pfizer AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Pfizer Main Business Overview
13.8.5 Pfizer Latest Developments
13.9 CSL Behring
13.9.1 CSL Behring Company Information
13.9.2 CSL Behring AAV-based Gene Therapy Products Product Portfolios and Specifications
13.9.3 CSL Behring AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 CSL Behring Main Business Overview
13.9.5 CSL Behring Latest Developments
13.10 Sangamo Therapeutics
13.10.1 Sangamo Therapeutics Company Information
13.10.2 Sangamo Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
13.10.3 Sangamo Therapeutics AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Sangamo Therapeutics Main Business Overview
13.10.5 Sangamo Therapeutics Latest Developments
13.11 Biogen
13.11.1 Biogen Company Information
13.11.2 Biogen AAV-based Gene Therapy Products Product Portfolios and Specifications
13.11.3 Biogen AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Biogen Main Business Overview
13.11.5 Biogen Latest Developments
13.12 Freeline Therapeutics
13.12.1 Freeline Therapeutics Company Information
13.12.2 Freeline Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
13.12.3 Freeline Therapeutics AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Freeline Therapeutics Main Business Overview
13.12.5 Freeline Therapeutics Latest Developments
13.13 Coave Therapeutics
13.13.1 Coave Therapeutics Company Information
13.13.2 Coave Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
13.13.3 Coave Therapeutics AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Coave Therapeutics Main Business Overview
13.13.5 Coave Therapeutics Latest Developments
13.14 MeiraGTx
13.14.1 MeiraGTx Company Information
13.14.2 MeiraGTx AAV-based Gene Therapy Products Product Portfolios and Specifications
13.14.3 MeiraGTx AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 MeiraGTx Main Business Overview
13.14.5 MeiraGTx Latest Developments
13.15 RegenxBio
13.15.1 RegenxBio Company Information
13.15.2 RegenxBio AAV-based Gene Therapy Products Product Portfolios and Specifications
13.15.3 RegenxBio AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 RegenxBio Main Business Overview
13.15.5 RegenxBio Latest Developments
13.16 Asklepios Biopharmaceutical
13.16.1 Asklepios Biopharmaceutical Company Information
13.16.2 Asklepios Biopharmaceutical AAV-based Gene Therapy Products Product Portfolios and Specifications
13.16.3 Asklepios Biopharmaceutical AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Asklepios Biopharmaceutical Main Business Overview
13.16.5 Asklepios Biopharmaceutical Latest Developments
13.17 Audentes Therapeutics
13.17.1 Audentes Therapeutics Company Information
13.17.2 Audentes Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
13.17.3 Audentes Therapeutics AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Audentes Therapeutics Main Business Overview
13.17.5 Audentes Therapeutics Latest Developments
13.18 Neurophth
13.18.1 Neurophth Company Information
13.18.2 Neurophth AAV-based Gene Therapy Products Product Portfolios and Specifications
13.18.3 Neurophth AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Neurophth Main Business Overview
13.18.5 Neurophth Latest Developments
13.19 Belief BioMed
13.19.1 Belief BioMed Company Information
13.19.2 Belief BioMed AAV-based Gene Therapy Products Product Portfolios and Specifications
13.19.3 Belief BioMed AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Belief BioMed Main Business Overview
13.19.5 Belief BioMed Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. AAV-based Gene Therapy Products Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. AAV-based Gene Therapy Products Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of AAV2
Table 4. Major Players of AAV8
Table 5. Major Players of AAV9
Table 6. Major Players of Others
Table 7. Global AAV-based Gene Therapy Products Sales by Type (2021-2026) & (Units)
Table 8. Global AAV-based Gene Therapy Products Sales Market Share by Type (2021-2026)
Table 9. Global AAV-based Gene Therapy Products Revenue by Type (2021-2026) & ($ million)
Table 10. Global AAV-based Gene Therapy Products Revenue Market Share by Type (2021-2026)
Table 11. Global AAV-based Gene Therapy Products Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global AAV-based Gene Therapy Products Sale by Application (2021-2026) & (Units)
Table 13. Global AAV-based Gene Therapy Products Sale Market Share by Application (2021-2026)
Table 14. Global AAV-based Gene Therapy Products Revenue by Application (2021-2026) & ($ million)
Table 15. Global AAV-based Gene Therapy Products Revenue Market Share by Application (2021-2026)
Table 16. Global AAV-based Gene Therapy Products Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global AAV-based Gene Therapy Products Sales by Company (2021-2026) & (Units)
Table 18. Global AAV-based Gene Therapy Products Sales Market Share by Company (2021-2026)
Table 19. Global AAV-based Gene Therapy Products Revenue by Company (2021-2026) & ($ millions)
Table 20. Global AAV-based Gene Therapy Products Revenue Market Share by Company (2021-2026)
Table 21. Global AAV-based Gene Therapy Products Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers AAV-based Gene Therapy Products Producing Area Distribution and Sales Area
Table 23. Players AAV-based Gene Therapy Products Products Offered
Table 24. AAV-based Gene Therapy Products Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global AAV-based Gene Therapy Products Sales by Geographic Region (2021-2026) & (Units)
Table 28. Global AAV-based Gene Therapy Products Sales Market Share Geographic Region (2021-2026)
Table 29. Global AAV-based Gene Therapy Products Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global AAV-based Gene Therapy Products Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global AAV-based Gene Therapy Products Sales by Country/Region (2021-2026) & (Units)
Table 32. Global AAV-based Gene Therapy Products Sales Market Share by Country/Region (2021-2026)
Table 33. Global AAV-based Gene Therapy Products Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global AAV-based Gene Therapy Products Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas AAV-based Gene Therapy Products Sales by Country (2021-2026) & (Units)
Table 36. Americas AAV-based Gene Therapy Products Sales Market Share by Country (2021-2026)
Table 37. Americas AAV-based Gene Therapy Products Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas AAV-based Gene Therapy Products Sales by Type (2021-2026) & (Units)
Table 39. Americas AAV-based Gene Therapy Products Sales by Application (2021-2026) & (Units)
Table 40. APAC AAV-based Gene Therapy Products Sales by Region (2021-2026) & (Units)
Table 41. APAC AAV-based Gene Therapy Products Sales Market Share by Region (2021-2026)
Table 42. APAC AAV-based Gene Therapy Products Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC AAV-based Gene Therapy Products Sales by Type (2021-2026) & (Units)
Table 44. APAC AAV-based Gene Therapy Products Sales by Application (2021-2026) & (Units)
Table 45. Europe AAV-based Gene Therapy Products Sales by Country (2021-2026) & (Units)
Table 46. Europe AAV-based Gene Therapy Products Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe AAV-based Gene Therapy Products Sales by Type (2021-2026) & (Units)
Table 48. Europe AAV-based Gene Therapy Products Sales by Application (2021-2026) & (Units)
Table 49. Middle East & Africa AAV-based Gene Therapy Products Sales by Country (2021-2026) & (Units)
Table 50. Middle East & Africa AAV-based Gene Therapy Products Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa AAV-based Gene Therapy Products Sales by Type (2021-2026) & (Units)
Table 52. Middle East & Africa AAV-based Gene Therapy Products Sales by Application (2021-2026) & (Units)
Table 53. Key Market Drivers & Growth Opportunities of AAV-based Gene Therapy Products
Table 54. Key Market Challenges & Risks of AAV-based Gene Therapy Products
Table 55. Key Industry Trends of AAV-based Gene Therapy Products
Table 56. AAV-based Gene Therapy Products Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. AAV-based Gene Therapy Products Distributors List
Table 59. AAV-based Gene Therapy Products Customer List
Table 60. Global AAV-based Gene Therapy Products Sales Forecast by Region (2027-2032) & (Units)
Table 61. Global AAV-based Gene Therapy Products Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas AAV-based Gene Therapy Products Sales Forecast by Country (2027-2032) & (Units)
Table 63. Americas AAV-based Gene Therapy Products Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC AAV-based Gene Therapy Products Sales Forecast by Region (2027-2032) & (Units)
Table 65. APAC AAV-based Gene Therapy Products Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe AAV-based Gene Therapy Products Sales Forecast by Country (2027-2032) & (Units)
Table 67. Europe AAV-based Gene Therapy Products Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa AAV-based Gene Therapy Products Sales Forecast by Country (2027-2032) & (Units)
Table 69. Middle East & Africa AAV-based Gene Therapy Products Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global AAV-based Gene Therapy Products Sales Forecast by Type (2027-2032) & (Units)
Table 71. Global AAV-based Gene Therapy Products Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global AAV-based Gene Therapy Products Sales Forecast by Application (2027-2032) & (Units)
Table 73. Global AAV-based Gene Therapy Products Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. uniQure Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 75. uniQure AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 76. uniQure AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. uniQure Main Business
Table 78. uniQure Latest Developments
Table 79. Spark Therapeutics Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 80. Spark Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 81. Spark Therapeutics AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Spark Therapeutics Main Business
Table 83. Spark Therapeutics Latest Developments
Table 84. AveXis (Novartis) Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 85. AveXis (Novartis) AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 86. AveXis (Novartis) AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. AveXis (Novartis) Main Business
Table 88. AveXis (Novartis) Latest Developments
Table 89. PTC Therapeutics Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 90. PTC Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 91. PTC Therapeutics AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. PTC Therapeutics Main Business
Table 93. PTC Therapeutics Latest Developments
Table 94. BioMarin Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 95. BioMarin AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 96. BioMarin AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. BioMarin Main Business
Table 98. BioMarin Latest Developments
Table 99. Sarepta Therapeutics Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 100. Sarepta Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 101. Sarepta Therapeutics AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Sarepta Therapeutics Main Business
Table 103. Sarepta Therapeutics Latest Developments
Table 104. Roche Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 105. Roche AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 106. Roche AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Roche Main Business
Table 108. Roche Latest Developments
Table 109. Pfizer Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 110. Pfizer AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 111. Pfizer AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Pfizer Main Business
Table 113. Pfizer Latest Developments
Table 114. CSL Behring Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 115. CSL Behring AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 116. CSL Behring AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. CSL Behring Main Business
Table 118. CSL Behring Latest Developments
Table 119. Sangamo Therapeutics Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 120. Sangamo Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 121. Sangamo Therapeutics AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Sangamo Therapeutics Main Business
Table 123. Sangamo Therapeutics Latest Developments
Table 124. Biogen Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 125. Biogen AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 126. Biogen AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Biogen Main Business
Table 128. Biogen Latest Developments
Table 129. Freeline Therapeutics Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 130. Freeline Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 131. Freeline Therapeutics AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. Freeline Therapeutics Main Business
Table 133. Freeline Therapeutics Latest Developments
Table 134. Coave Therapeutics Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 135. Coave Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 136. Coave Therapeutics AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Coave Therapeutics Main Business
Table 138. Coave Therapeutics Latest Developments
Table 139. MeiraGTx Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 140. MeiraGTx AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 141. MeiraGTx AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 142. MeiraGTx Main Business
Table 143. MeiraGTx Latest Developments
Table 144. RegenxBio Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 145. RegenxBio AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 146. RegenxBio AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 147. RegenxBio Main Business
Table 148. RegenxBio Latest Developments
Table 149. Asklepios Biopharmaceutical Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 150. Asklepios Biopharmaceutical AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 151. Asklepios Biopharmaceutical AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 152. Asklepios Biopharmaceutical Main Business
Table 153. Asklepios Biopharmaceutical Latest Developments
Table 154. Audentes Therapeutics Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 155. Audentes Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 156. Audentes Therapeutics AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 157. Audentes Therapeutics Main Business
Table 158. Audentes Therapeutics Latest Developments
Table 159. Neurophth Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 160. Neurophth AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 161. Neurophth AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 162. Neurophth Main Business
Table 163. Neurophth Latest Developments
Table 164. Belief BioMed Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 165. Belief BioMed AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 166. Belief BioMed AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 167. Belief BioMed Main Business
Table 168. Belief BioMed Latest Developments
Table 1. AAV-based Gene Therapy Products Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. AAV-based Gene Therapy Products Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of AAV2
Table 4. Major Players of AAV8
Table 5. Major Players of AAV9
Table 6. Major Players of Others
Table 7. Global AAV-based Gene Therapy Products Sales by Type (2021-2026) & (Units)
Table 8. Global AAV-based Gene Therapy Products Sales Market Share by Type (2021-2026)
Table 9. Global AAV-based Gene Therapy Products Revenue by Type (2021-2026) & ($ million)
Table 10. Global AAV-based Gene Therapy Products Revenue Market Share by Type (2021-2026)
Table 11. Global AAV-based Gene Therapy Products Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global AAV-based Gene Therapy Products Sale by Application (2021-2026) & (Units)
Table 13. Global AAV-based Gene Therapy Products Sale Market Share by Application (2021-2026)
Table 14. Global AAV-based Gene Therapy Products Revenue by Application (2021-2026) & ($ million)
Table 15. Global AAV-based Gene Therapy Products Revenue Market Share by Application (2021-2026)
Table 16. Global AAV-based Gene Therapy Products Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global AAV-based Gene Therapy Products Sales by Company (2021-2026) & (Units)
Table 18. Global AAV-based Gene Therapy Products Sales Market Share by Company (2021-2026)
Table 19. Global AAV-based Gene Therapy Products Revenue by Company (2021-2026) & ($ millions)
Table 20. Global AAV-based Gene Therapy Products Revenue Market Share by Company (2021-2026)
Table 21. Global AAV-based Gene Therapy Products Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers AAV-based Gene Therapy Products Producing Area Distribution and Sales Area
Table 23. Players AAV-based Gene Therapy Products Products Offered
Table 24. AAV-based Gene Therapy Products Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global AAV-based Gene Therapy Products Sales by Geographic Region (2021-2026) & (Units)
Table 28. Global AAV-based Gene Therapy Products Sales Market Share Geographic Region (2021-2026)
Table 29. Global AAV-based Gene Therapy Products Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global AAV-based Gene Therapy Products Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global AAV-based Gene Therapy Products Sales by Country/Region (2021-2026) & (Units)
Table 32. Global AAV-based Gene Therapy Products Sales Market Share by Country/Region (2021-2026)
Table 33. Global AAV-based Gene Therapy Products Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global AAV-based Gene Therapy Products Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas AAV-based Gene Therapy Products Sales by Country (2021-2026) & (Units)
Table 36. Americas AAV-based Gene Therapy Products Sales Market Share by Country (2021-2026)
Table 37. Americas AAV-based Gene Therapy Products Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas AAV-based Gene Therapy Products Sales by Type (2021-2026) & (Units)
Table 39. Americas AAV-based Gene Therapy Products Sales by Application (2021-2026) & (Units)
Table 40. APAC AAV-based Gene Therapy Products Sales by Region (2021-2026) & (Units)
Table 41. APAC AAV-based Gene Therapy Products Sales Market Share by Region (2021-2026)
Table 42. APAC AAV-based Gene Therapy Products Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC AAV-based Gene Therapy Products Sales by Type (2021-2026) & (Units)
Table 44. APAC AAV-based Gene Therapy Products Sales by Application (2021-2026) & (Units)
Table 45. Europe AAV-based Gene Therapy Products Sales by Country (2021-2026) & (Units)
Table 46. Europe AAV-based Gene Therapy Products Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe AAV-based Gene Therapy Products Sales by Type (2021-2026) & (Units)
Table 48. Europe AAV-based Gene Therapy Products Sales by Application (2021-2026) & (Units)
Table 49. Middle East & Africa AAV-based Gene Therapy Products Sales by Country (2021-2026) & (Units)
Table 50. Middle East & Africa AAV-based Gene Therapy Products Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa AAV-based Gene Therapy Products Sales by Type (2021-2026) & (Units)
Table 52. Middle East & Africa AAV-based Gene Therapy Products Sales by Application (2021-2026) & (Units)
Table 53. Key Market Drivers & Growth Opportunities of AAV-based Gene Therapy Products
Table 54. Key Market Challenges & Risks of AAV-based Gene Therapy Products
Table 55. Key Industry Trends of AAV-based Gene Therapy Products
Table 56. AAV-based Gene Therapy Products Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. AAV-based Gene Therapy Products Distributors List
Table 59. AAV-based Gene Therapy Products Customer List
Table 60. Global AAV-based Gene Therapy Products Sales Forecast by Region (2027-2032) & (Units)
Table 61. Global AAV-based Gene Therapy Products Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas AAV-based Gene Therapy Products Sales Forecast by Country (2027-2032) & (Units)
Table 63. Americas AAV-based Gene Therapy Products Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC AAV-based Gene Therapy Products Sales Forecast by Region (2027-2032) & (Units)
Table 65. APAC AAV-based Gene Therapy Products Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe AAV-based Gene Therapy Products Sales Forecast by Country (2027-2032) & (Units)
Table 67. Europe AAV-based Gene Therapy Products Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa AAV-based Gene Therapy Products Sales Forecast by Country (2027-2032) & (Units)
Table 69. Middle East & Africa AAV-based Gene Therapy Products Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global AAV-based Gene Therapy Products Sales Forecast by Type (2027-2032) & (Units)
Table 71. Global AAV-based Gene Therapy Products Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global AAV-based Gene Therapy Products Sales Forecast by Application (2027-2032) & (Units)
Table 73. Global AAV-based Gene Therapy Products Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. uniQure Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 75. uniQure AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 76. uniQure AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. uniQure Main Business
Table 78. uniQure Latest Developments
Table 79. Spark Therapeutics Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 80. Spark Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 81. Spark Therapeutics AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Spark Therapeutics Main Business
Table 83. Spark Therapeutics Latest Developments
Table 84. AveXis (Novartis) Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 85. AveXis (Novartis) AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 86. AveXis (Novartis) AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. AveXis (Novartis) Main Business
Table 88. AveXis (Novartis) Latest Developments
Table 89. PTC Therapeutics Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 90. PTC Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 91. PTC Therapeutics AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. PTC Therapeutics Main Business
Table 93. PTC Therapeutics Latest Developments
Table 94. BioMarin Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 95. BioMarin AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 96. BioMarin AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. BioMarin Main Business
Table 98. BioMarin Latest Developments
Table 99. Sarepta Therapeutics Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 100. Sarepta Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 101. Sarepta Therapeutics AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Sarepta Therapeutics Main Business
Table 103. Sarepta Therapeutics Latest Developments
Table 104. Roche Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 105. Roche AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 106. Roche AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Roche Main Business
Table 108. Roche Latest Developments
Table 109. Pfizer Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 110. Pfizer AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 111. Pfizer AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Pfizer Main Business
Table 113. Pfizer Latest Developments
Table 114. CSL Behring Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 115. CSL Behring AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 116. CSL Behring AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. CSL Behring Main Business
Table 118. CSL Behring Latest Developments
Table 119. Sangamo Therapeutics Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 120. Sangamo Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 121. Sangamo Therapeutics AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Sangamo Therapeutics Main Business
Table 123. Sangamo Therapeutics Latest Developments
Table 124. Biogen Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 125. Biogen AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 126. Biogen AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Biogen Main Business
Table 128. Biogen Latest Developments
Table 129. Freeline Therapeutics Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 130. Freeline Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 131. Freeline Therapeutics AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. Freeline Therapeutics Main Business
Table 133. Freeline Therapeutics Latest Developments
Table 134. Coave Therapeutics Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 135. Coave Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 136. Coave Therapeutics AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Coave Therapeutics Main Business
Table 138. Coave Therapeutics Latest Developments
Table 139. MeiraGTx Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 140. MeiraGTx AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 141. MeiraGTx AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 142. MeiraGTx Main Business
Table 143. MeiraGTx Latest Developments
Table 144. RegenxBio Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 145. RegenxBio AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 146. RegenxBio AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 147. RegenxBio Main Business
Table 148. RegenxBio Latest Developments
Table 149. Asklepios Biopharmaceutical Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 150. Asklepios Biopharmaceutical AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 151. Asklepios Biopharmaceutical AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 152. Asklepios Biopharmaceutical Main Business
Table 153. Asklepios Biopharmaceutical Latest Developments
Table 154. Audentes Therapeutics Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 155. Audentes Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 156. Audentes Therapeutics AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 157. Audentes Therapeutics Main Business
Table 158. Audentes Therapeutics Latest Developments
Table 159. Neurophth Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 160. Neurophth AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 161. Neurophth AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 162. Neurophth Main Business
Table 163. Neurophth Latest Developments
Table 164. Belief BioMed Basic Information, AAV-based Gene Therapy Products Manufacturing Base, Sales Area and Its Competitors
Table 165. Belief BioMed AAV-based Gene Therapy Products Product Portfolios and Specifications
Table 166. Belief BioMed AAV-based Gene Therapy Products Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 167. Belief BioMed Main Business
Table 168. Belief BioMed Latest Developments
LIST OF FIGURES
Figure 1. Picture of AAV-based Gene Therapy Products
Figure 2. AAV-based Gene Therapy Products Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global AAV-based Gene Therapy Products Sales Growth Rate 2021-2032 (Units)
Figure 7. Global AAV-based Gene Therapy Products Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. AAV-based Gene Therapy Products Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. AAV-based Gene Therapy Products Sales Market Share by Country/Region (2025)
Figure 10. AAV-based Gene Therapy Products Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of AAV2
Figure 12. Product Picture of AAV8
Figure 13. Product Picture of AAV9
Figure 14. Product Picture of Others
Figure 15. Global AAV-based Gene Therapy Products Sales Market Share by Type in 2026
Figure 16. Global AAV-based Gene Therapy Products Revenue Market Share by Type (2021-2026)
Figure 17. AAV-based Gene Therapy Products Consumed in Haematology
Figure 18. Global AAV-based Gene Therapy Products Market: Haematology (2021-2026) & (Units)
Figure 19. AAV-based Gene Therapy Products Consumed in Ophthalmology
Figure 20. Global AAV-based Gene Therapy Products Market: Ophthalmology (2021-2026) & (Units)
Figure 21. AAV-based Gene Therapy Products Consumed in Neurology
Figure 22. Global AAV-based Gene Therapy Products Market: Neurology (2021-2026) & (Units)
Figure 23. AAV-based Gene Therapy Products Consumed in Musculoskeletal
Figure 24. Global AAV-based Gene Therapy Products Market: Musculoskeletal (2021-2026) & (Units)
Figure 25. AAV-based Gene Therapy Products Consumed in Others
Figure 26. Global AAV-based Gene Therapy Products Market: Others (2021-2026) & (Units)
Figure 27. Global AAV-based Gene Therapy Products Sale Market Share by Application (2025)
Figure 28. Global AAV-based Gene Therapy Products Revenue Market Share by Application in 2026
Figure 29. AAV-based Gene Therapy Products Sales by Company in 2026 (Units)
Figure 30. Global AAV-based Gene Therapy Products Sales Market Share by Company in 2026
Figure 31. AAV-based Gene Therapy Products Revenue by Company in 2026 ($ millions)
Figure 32. Global AAV-based Gene Therapy Products Revenue Market Share by Company in 2026
Figure 33. Global AAV-based Gene Therapy Products Sales Market Share by Geographic Region (2021-2026)
Figure 34. Global AAV-based Gene Therapy Products Revenue Market Share by Geographic Region in 2026
Figure 35. Americas AAV-based Gene Therapy Products Sales 2021-2026 (Units)
Figure 36. Americas AAV-based Gene Therapy Products Revenue 2021-2026 ($ millions)
Figure 37. APAC AAV-based Gene Therapy Products Sales 2021-2026 (Units)
Figure 38. APAC AAV-based Gene Therapy Products Revenue 2021-2026 ($ millions)
Figure 39. Europe AAV-based Gene Therapy Products Sales 2021-2026 (Units)
Figure 40. Europe AAV-based Gene Therapy Products Revenue 2021-2026 ($ millions)
Figure 41. Middle East & Africa AAV-based Gene Therapy Products Sales 2021-2026 (Units)
Figure 42. Middle East & Africa AAV-based Gene Therapy Products Revenue 2021-2026 ($ millions)
Figure 43. Americas AAV-based Gene Therapy Products Sales Market Share by Country in 2026
Figure 44. Americas AAV-based Gene Therapy Products Revenue Market Share by Country (2021-2026)
Figure 45. Americas AAV-based Gene Therapy Products Sales Market Share by Type (2021-2026)
Figure 46. Americas AAV-based Gene Therapy Products Sales Market Share by Application (2021-2026)
Figure 47. United States AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 48. Canada AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 49. Mexico AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 50. Brazil AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 51. APAC AAV-based Gene Therapy Products Sales Market Share by Region in 2026
Figure 52. APAC AAV-based Gene Therapy Products Revenue Market Share by Region (2021-2026)
Figure 53. APAC AAV-based Gene Therapy Products Sales Market Share by Type (2021-2026)
Figure 54. APAC AAV-based Gene Therapy Products Sales Market Share by Application (2021-2026)
Figure 55. China AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 56. Japan AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 57. South Korea AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 58. Southeast Asia AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 59. India AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 60. Australia AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 61. China Taiwan AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 62. Europe AAV-based Gene Therapy Products Sales Market Share by Country in 2026
Figure 63. Europe AAV-based Gene Therapy Products Revenue Market Share by Country (2021-2026)
Figure 64. Europe AAV-based Gene Therapy Products Sales Market Share by Type (2021-2026)
Figure 65. Europe AAV-based Gene Therapy Products Sales Market Share by Application (2021-2026)
Figure 66. Germany AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 67. France AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 68. UK AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 69. Italy AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 70. Russia AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 71. Middle East & Africa AAV-based Gene Therapy Products Sales Market Share by Country (2021-2026)
Figure 72. Middle East & Africa AAV-based Gene Therapy Products Sales Market Share by Type (2021-2026)
Figure 73. Middle East & Africa AAV-based Gene Therapy Products Sales Market Share by Application (2021-2026)
Figure 74. Egypt AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 75. South Africa AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 76. Israel AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 77. Turkey AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 78. GCC Countries AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 79. Manufacturing Cost Structure Analysis of AAV-based Gene Therapy Products in 2026
Figure 80. Manufacturing Process Analysis of AAV-based Gene Therapy Products
Figure 81. Industry Chain Structure of AAV-based Gene Therapy Products
Figure 82. Channels of Distribution
Figure 83. Global AAV-based Gene Therapy Products Sales Market Forecast by Region (2027-2032)
Figure 84. Global AAV-based Gene Therapy Products Revenue Market Share Forecast by Region (2027-2032)
Figure 85. Global AAV-based Gene Therapy Products Sales Market Share Forecast by Type (2027-2032)
Figure 86. Global AAV-based Gene Therapy Products Revenue Market Share Forecast by Type (2027-2032)
Figure 87. Global AAV-based Gene Therapy Products Sales Market Share Forecast by Application (2027-2032)
Figure 88. Global AAV-based Gene Therapy Products Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of AAV-based Gene Therapy Products
Figure 2. AAV-based Gene Therapy Products Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global AAV-based Gene Therapy Products Sales Growth Rate 2021-2032 (Units)
Figure 7. Global AAV-based Gene Therapy Products Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. AAV-based Gene Therapy Products Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. AAV-based Gene Therapy Products Sales Market Share by Country/Region (2025)
Figure 10. AAV-based Gene Therapy Products Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of AAV2
Figure 12. Product Picture of AAV8
Figure 13. Product Picture of AAV9
Figure 14. Product Picture of Others
Figure 15. Global AAV-based Gene Therapy Products Sales Market Share by Type in 2026
Figure 16. Global AAV-based Gene Therapy Products Revenue Market Share by Type (2021-2026)
Figure 17. AAV-based Gene Therapy Products Consumed in Haematology
Figure 18. Global AAV-based Gene Therapy Products Market: Haematology (2021-2026) & (Units)
Figure 19. AAV-based Gene Therapy Products Consumed in Ophthalmology
Figure 20. Global AAV-based Gene Therapy Products Market: Ophthalmology (2021-2026) & (Units)
Figure 21. AAV-based Gene Therapy Products Consumed in Neurology
Figure 22. Global AAV-based Gene Therapy Products Market: Neurology (2021-2026) & (Units)
Figure 23. AAV-based Gene Therapy Products Consumed in Musculoskeletal
Figure 24. Global AAV-based Gene Therapy Products Market: Musculoskeletal (2021-2026) & (Units)
Figure 25. AAV-based Gene Therapy Products Consumed in Others
Figure 26. Global AAV-based Gene Therapy Products Market: Others (2021-2026) & (Units)
Figure 27. Global AAV-based Gene Therapy Products Sale Market Share by Application (2025)
Figure 28. Global AAV-based Gene Therapy Products Revenue Market Share by Application in 2026
Figure 29. AAV-based Gene Therapy Products Sales by Company in 2026 (Units)
Figure 30. Global AAV-based Gene Therapy Products Sales Market Share by Company in 2026
Figure 31. AAV-based Gene Therapy Products Revenue by Company in 2026 ($ millions)
Figure 32. Global AAV-based Gene Therapy Products Revenue Market Share by Company in 2026
Figure 33. Global AAV-based Gene Therapy Products Sales Market Share by Geographic Region (2021-2026)
Figure 34. Global AAV-based Gene Therapy Products Revenue Market Share by Geographic Region in 2026
Figure 35. Americas AAV-based Gene Therapy Products Sales 2021-2026 (Units)
Figure 36. Americas AAV-based Gene Therapy Products Revenue 2021-2026 ($ millions)
Figure 37. APAC AAV-based Gene Therapy Products Sales 2021-2026 (Units)
Figure 38. APAC AAV-based Gene Therapy Products Revenue 2021-2026 ($ millions)
Figure 39. Europe AAV-based Gene Therapy Products Sales 2021-2026 (Units)
Figure 40. Europe AAV-based Gene Therapy Products Revenue 2021-2026 ($ millions)
Figure 41. Middle East & Africa AAV-based Gene Therapy Products Sales 2021-2026 (Units)
Figure 42. Middle East & Africa AAV-based Gene Therapy Products Revenue 2021-2026 ($ millions)
Figure 43. Americas AAV-based Gene Therapy Products Sales Market Share by Country in 2026
Figure 44. Americas AAV-based Gene Therapy Products Revenue Market Share by Country (2021-2026)
Figure 45. Americas AAV-based Gene Therapy Products Sales Market Share by Type (2021-2026)
Figure 46. Americas AAV-based Gene Therapy Products Sales Market Share by Application (2021-2026)
Figure 47. United States AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 48. Canada AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 49. Mexico AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 50. Brazil AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 51. APAC AAV-based Gene Therapy Products Sales Market Share by Region in 2026
Figure 52. APAC AAV-based Gene Therapy Products Revenue Market Share by Region (2021-2026)
Figure 53. APAC AAV-based Gene Therapy Products Sales Market Share by Type (2021-2026)
Figure 54. APAC AAV-based Gene Therapy Products Sales Market Share by Application (2021-2026)
Figure 55. China AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 56. Japan AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 57. South Korea AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 58. Southeast Asia AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 59. India AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 60. Australia AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 61. China Taiwan AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 62. Europe AAV-based Gene Therapy Products Sales Market Share by Country in 2026
Figure 63. Europe AAV-based Gene Therapy Products Revenue Market Share by Country (2021-2026)
Figure 64. Europe AAV-based Gene Therapy Products Sales Market Share by Type (2021-2026)
Figure 65. Europe AAV-based Gene Therapy Products Sales Market Share by Application (2021-2026)
Figure 66. Germany AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 67. France AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 68. UK AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 69. Italy AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 70. Russia AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 71. Middle East & Africa AAV-based Gene Therapy Products Sales Market Share by Country (2021-2026)
Figure 72. Middle East & Africa AAV-based Gene Therapy Products Sales Market Share by Type (2021-2026)
Figure 73. Middle East & Africa AAV-based Gene Therapy Products Sales Market Share by Application (2021-2026)
Figure 74. Egypt AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 75. South Africa AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 76. Israel AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 77. Turkey AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 78. GCC Countries AAV-based Gene Therapy Products Revenue Growth 2021-2026 ($ millions)
Figure 79. Manufacturing Cost Structure Analysis of AAV-based Gene Therapy Products in 2026
Figure 80. Manufacturing Process Analysis of AAV-based Gene Therapy Products
Figure 81. Industry Chain Structure of AAV-based Gene Therapy Products
Figure 82. Channels of Distribution
Figure 83. Global AAV-based Gene Therapy Products Sales Market Forecast by Region (2027-2032)
Figure 84. Global AAV-based Gene Therapy Products Revenue Market Share Forecast by Region (2027-2032)
Figure 85. Global AAV-based Gene Therapy Products Sales Market Share Forecast by Type (2027-2032)
Figure 86. Global AAV-based Gene Therapy Products Revenue Market Share Forecast by Type (2027-2032)
Figure 87. Global AAV-based Gene Therapy Products Sales Market Share Forecast by Application (2027-2032)
Figure 88. Global AAV-based Gene Therapy Products Revenue Market Share Forecast by Application (2027-2032)
